Dysplasia is the presence of abnormal cells in a tissue or organ. Under a microscope, dysplastic cells look different from normal cells in their size, shape, and organization, but they haven’t become cancer. Think of it as a warning sign: the cells are misbehaving, growing in disorderly patterns, but they haven’t crossed the line into invading surrounding tissue. Dysplasia can occur in nearly any part of the body, from the cervix and esophagus to bone marrow and hip joints, and the term means something slightly different depending on where it shows up.
How Dysplastic Cells Differ From Normal Ones
Normal tissue has a predictable architecture. Cells are uniform in size, divide at a controlled rate, and stack in orderly layers. In dysplasia, that organization breaks down. The cells themselves may vary wildly in size and shape, their nuclei (the control center of each cell) are often enlarged and darker-staining, and the ratio of nucleus to the rest of the cell shifts upward. Cells also lose their polarity, meaning they no longer orient themselves in the same direction the way healthy cells do.
Beyond individual cell changes, the tissue’s overall structure becomes disorganized. Layers that should mature as they move toward the surface instead look immature throughout. Cells may start dividing in places where division doesn’t normally happen, and you can see abnormal division patterns that wouldn’t appear in healthy tissue. The World Health Organization lists these architectural and cellular abnormalities as the formal criteria pathologists use to make the diagnosis.
Crucially, dysplasia is considered reversible. If the stimulus causing the abnormal growth is removed, such as an infection or chronic irritation, the tissue can return to normal. This distinguishes it from true cancer (neoplasia), which grows autonomously and doesn’t need an ongoing trigger.
Dysplasia vs. Hyperplasia vs. Neoplasia
These three terms describe a spectrum of abnormal cell behavior, and understanding where dysplasia fits helps clarify what it means for your health. Hyperplasia is simply an increase in the number of cells. The cells themselves are normal in appearance and arrangement; there are just more of them. Dysplasia goes a step further: the cells are not only growing abnormally but also look abnormal under a microscope, with changes in size, shape, and organization. Both hyperplasia and dysplasia are reversible.
Neoplasia, by contrast, is irreversible. It refers to genuinely new, autonomous growth. A benign neoplasm (tumor) stays put, while a malignant neoplasm invades through the basement membrane, the thin boundary separating surface tissue from deeper layers, and can spread to other parts of the body. Dysplasia sits between hyperplasia and neoplasia on this continuum, which is why doctors monitor it closely.
How Dysplasia Is Graded
Not all dysplasia carries the same risk. Pathologists grade it as mild, moderate, or severe based on how much of the tissue’s thickness is affected and how abnormal the cells look. In mild dysplasia, the disorganization is confined to roughly the lower third of the tissue layer. In moderate dysplasia, it extends into the middle third. In severe dysplasia, more than two-thirds of the tissue shows abnormal architecture and cell changes.
When the entire thickness of the tissue is affected but the abnormal cells still haven’t broken through the basement membrane, the condition is called carcinoma in situ. This is essentially the last stop before invasive cancer. The grading system matters because it directly influences treatment decisions and how aggressively doctors recommend follow-up.
Where Dysplasia Commonly Occurs
Cervical Dysplasia
This is one of the most well-known forms, largely because routine Pap smears are designed to catch it early. Cervical dysplasia is classified as CIN 1, CIN 2, or CIN 3 (cervical intraepithelial neoplasia). CIN 1 is low-grade, involving only the lower third of the cervical lining. CIN 2 and CIN 3 are high-grade, with abnormal cells extending through more of the tissue’s thickness. Dysplasia becomes cervical cancer only when those cells break through the basement membrane and invade deeper tissue. Most CIN 1 resolves on its own, particularly in younger women, while CIN 2 and CIN 3 are more likely to require treatment.
Barrett’s Esophagus
Long-standing acid reflux can change the lining of the lower esophagus, a condition called Barrett’s esophagus. When dysplasia develops in this changed tissue, it’s graded as low-grade or high-grade. Low-grade dysplasia shows mildly disorganized cells with some increase in nuclear size but cells that still maintain their general orientation. High-grade dysplasia is more concerning: cells lose their polarity entirely, divide abnormally even near the tissue surface, and the glands in the tissue become crowded and irregularly shaped. The distinction matters because high-grade dysplasia in Barrett’s esophagus carries a meaningful risk of progressing to esophageal cancer.
Oral Dysplasia
White or red patches in the mouth can sometimes harbor dysplasia. The risk of these lesions turning into cancer depends heavily on the grade. Mild oral dysplasia has a malignant transformation rate of about 6%, moderate around 18%, and severe dysplasia or carcinoma in situ around 39%. Treatment significantly lowers these numbers. One study found that patients with high-grade oral dysplasia who underwent surgical excision or laser treatment had a transformation rate of about 12%, compared to nearly 29% in untreated patients.
Hip Dysplasia
The word “dysplasia” also applies outside of cancer pathology. Developmental dysplasia of the hip (DDH) refers to a hip joint that didn’t form properly, leaving the socket too shallow to fully cover the ball of the thigh bone. In newborns, doctors screen for it using physical maneuvers that check whether the hip can be pushed out of or back into the socket. Ultrasound is the preferred imaging tool for infants under six months, while X-rays become more useful in older children and adults. In adults, the angle of coverage of the hip socket is measured on imaging: a center-edge angle under 20 degrees is considered abnormal. Left untreated, hip dysplasia can lead to pain, limping, and early-onset arthritis.
Ectodermal Dysplasia
This is a group of inherited conditions affecting structures that develop from the outer layer of the embryo: skin, sweat glands, hair, teeth, and nails. People with ectodermal dysplasia may have missing or cone-shaped teeth, thinner enamel that’s prone to cavities, reduced sweating (which can make it hard to regulate body temperature), sparse hair, and dry mouth from reduced saliva production. Some forms also involve cleft lip or palate. Unlike the other types discussed here, ectodermal dysplasia is genetic and not related to cancer risk.
Myelodysplastic Syndromes
When dysplasia occurs in the bone marrow, it affects the production of blood cells. Myelodysplastic syndromes (MDS) are a group of conditions where the bone marrow produces abnormal, immature blood cells that don’t function properly. This can lead to low red blood cell counts (causing fatigue), low white blood cell counts (increasing infection risk), or low platelet counts (leading to easy bruising or bleeding). MDS is classified based on how many cell lines are affected and the percentage of immature cells (blasts) in the bone marrow. When blasts stay below 5%, the disease is categorized as low-blast MDS. Higher blast percentages, from 5 to 19%, indicate more advanced disease with a greater risk of progressing to acute leukemia.
How Dysplasia Is Diagnosed
A biopsy is the only way to definitively diagnose dysplasia. A small sample of tissue is removed and examined under a microscope by a pathologist, who looks for the characteristic changes in cell appearance and tissue architecture described above. There is no blood test or imaging scan that can confirm dysplasia on its own.
Microscopic assessment remains the gold standard, though it’s inherently subjective. Two pathologists looking at the same tissue sample may sometimes disagree on the grade. Pathologists can use special staining techniques involving specific protein markers to help distinguish between benign changes and true dysplasia, but these markers aren’t always reliable in individual cases. This is why second opinions on biopsy results are common, particularly when the grade determines whether surgery is recommended.
How Dysplasia Is Treated
Treatment depends entirely on the type, location, and grade. Low-grade dysplasia in many locations is managed with watchful waiting and regular follow-up biopsies, since it often resolves on its own or remains stable for years. High-grade dysplasia typically requires intervention because the risk of progression to cancer is substantial.
For dysplasia in accessible linings like the esophagus, minimally invasive endoscopic techniques have largely replaced major surgery. Radiofrequency ablation uses heat energy delivered through an endoscope to destroy the abnormal tissue. When there’s a visible raised lesion, doctors often combine ablation with endoscopic mucosal resection, where the abnormal area is physically removed through the endoscope. This combination produces higher remission rates without significantly increasing complications compared to ablation alone. Esophageal surgery, once the standard approach, is now generally reserved for cases where cancer has already developed, given its higher rates of complications.
For cervical dysplasia, high-grade lesions are commonly treated with procedures that remove or destroy the abnormal area of the cervix, after which the tissue typically heals and returns to normal. Oral dysplasia may be treated with surgical excision or laser therapy. Hip dysplasia in infants is managed with bracing or harnesses to hold the joint in the correct position during growth, while adults with symptomatic hip dysplasia may eventually need surgical correction. Myelodysplastic syndromes have their own treatment pathway that depends on the specific subtype and the patient’s overall risk profile, ranging from supportive care like transfusions to more intensive therapies aimed at the bone marrow itself.